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Abstract 
 
Positive allosteric modulators of centrally expressed nicotinic acetylcholine receptors 
have therapeutic potentials in areas of cognition, motor function and reward. Several 
chemical classes of allosteric modulators that are selective for α7 nicotinic receptors have 
been characterised, but potentiators for the most widely expressed α4β2 nicotinic receptor 
subtype are few and less defined, owing probably to the difficulty to achieve selectivity 
over other heteromeric receptor subtypes. 2087101 ((2-amino-5-keto)thiazole) is a potent 
potentiator of both α7 and α4β2 receptors and it has selectivity against the α3β4 subtype, 
which may be responsible for the undesirable peripheral side effects. To further 
characterise its ability to differentiate between native nicotinic receptors, we examined the 
effects of 2087101 on α7, α4β2* and α3β4* receptor-mediated responses in the rat brain 
in electrophysiological and neurochemical experiments. 2087101 significantly potentiated 
agonist-induced, α7 and non-α7 receptor-mediated, GABAergic postsynaptic currents in 
cultured hippocampal neurones, but not the nicotine-stimulated [3H]noradrenaline release 
from hippocampal slices, which was primarily mediated by α3β4* receptors, confirming 
its selectivity for α7 and α4β2* receptors in native systems. 2087101 also significantly 
enhanced nicotine-stimulated firing increase in dopamine neurones of the ventral 
tegmental area, an effect that was dihydro-β-erythroidine-sensitive and thereby mediated 
by α4β2* nicotinic receptors. 2087101 can therefore enhance native nicotinic activities 
mediated by α7 and α4β2*, but not α3β4* receptors, showing its unique ability to 
discriminate between native heteromeric nicotinic receptor subtypes and its therapeutic 
potential for treating brain disorders by concurrent modulation of both α7 and α4β2* 
nicotinic receptors.  
  
 Index words: positive allosteric modulator, nicotinic acetylcholine receptors, ventral 
tegmental area, hippocampus, dopamine neuron firing, GABA, noradrenaline release,  
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1. Introduction 
Native neuronal nicotinic acetylcholine receptors include the homomeric α7 
receptors and heteromeric α4β2*, α3β4*, α6β2* and α4α6β2* receptors which possibly 
contain additional subunits (*) such as α5, α2 and β3 (Zoli et al., 1998, Grady et al., 
2007). The α4β2* and α7 receptors are the two main subtypes in the brain and their 
activation can modulate various neuronal processes and functions (Vizi and Kiss, 1998). 
In particular, loss of nicotinic receptor functions can cause deficits in cognitive, motor and 
reward functions in the elderly population and particularly in patients suffering from 
Alzheimer’s disease (Perry et al., 2000) and schizophrenia (Freedman et al., 2000). 
Treatments that elevate levels of endogenous acetylcholine by inhibition of 
acetylcholinesterase are used clinically to alleviate symptoms of Alzheimer’s disease. 
Recently, positive allosteric modulation has also been proposed as a favoured therapeutic 
strategy via functional enhancement of nicotinic receptors (Albuquerque et al., 2009). 
Positive allosteric modulators induce conformational modifications of receptors at 
a site away from the orthosteric agonist binding site to enhance receptor function without 
causing direct receptor activation, inactivation or desensitisation, thus preserving the high 
temporal and spatial resolutions of endogenous nicotinic transmission (Albuquerque et al., 
2009). Recently, α7-selective positive modulators such as PNU-120596 (Hurst et al., 
2005), compound 6 (Ng et al., 2007) and NS-1738 (Timmermann et al., 2007) have been 
shown to enhance receptor current, improve cognitive functions and reduce hippocampal 
gating deficits in rodent experimental models, hence providing validation for the potential 
therapeutic values of nicotinic positive modulators.  
In contrast, few selective modulators have been identified and characterised for the 
most widely expressed neuronal α4β2* receptors. Although the endogenous steroid 17-
estradiol (Curtis et al., 2002), a Flustra foliacea metabolite deformylflustrabromine (Sala 
et al., 2005), and a number of carbamates and piperidines (Albrecht et al., 2008, Springer 
et al., 2008) have been discovered, their molecular mechanisms and functional effects on 
native brain receptors are yet to be characterised. The difficulty to obtain α4β2*-selective 
compounds is probably owing to the lack of selectivity against other heteromeric 
receptors, especially the α3β4* receptors, which are predominantly expressed in 
ganglionic neurones to mediate many off-target side effects of nicotinic ligands.  
2087101, a (2-amino-5-keto)thiazole, has been shown to potentiate α4β2, α7, 
α4β4 and α2β4, but not α3β4 or α1-containing muscle nicotinic receptors in mammalian 
cell lines and Xenopus oocytes (Broad et al., 2006). On α4β2 receptors, up to 8 fold 
potentiation of the receptor current was observed at a low acetylcholine concentration. 
Recently, the allosteric binding site of 2087101 on α7 receptors has been located to an 
intrasubunit cavity at the transmembrane region, providing a molecular basis for its 
allosteric action (Young et al., 2008). In the central nervous system where the expression 
of α4β4 and α2β4 is limited, 2087101 may show considerable selectivity for α4β2* and 
α7 but not α3β4* nicotinic receptors. To define its potential clinical applications we 
examined the effects of 2087101 on native α4β2*, α7 and α3β4* nicotinic receptor-
mediated processes in the rat brain. 
2. Materials and Methods 
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Animal tissues were prepared following procedures in compliance with the UK Animal 
(Scientific Procedure) Act 1986. 
 
2.1 Patch-clamp recordings in rat hippocampal neuronal culture 
 
Primary cultures of hippocampal neurones were prepared from newborn (1- to 2-day 
old) Wistar rats (Harlan, UK) with modified procedures (Alkondon and Albuquerque, 
1993). The brains were removed following decapitation and hippocampi were rapidly 
dissected and cut for enzymatic digestion in PBS solution containing 0.5 mg/ml papain 
(Sigma-Aldrich, Poole, UK) and 0.25 mg/ml deoxyribonuclease (DNAse I, Sigma-
Aldrich, Poole, UK) for 20 min at 37oC. The papain solution was replaced with 2 ml 
Dulbecco’s Modified Eagle’s Medium (DMEM, PAA Laboratories GmbH) supplemented 
with 10% heat-inactivated foetal bovine serum (FBS, Sigma), 10000 Units/ml penicillin, 
10000 μg/ml streptomycin, and 29.2 mg/ml L-glutamine (PSG, Invitrogen, Paisley, UK). 
The digested tissue was then gently triturated by suction using a sterile glass Pasteur 
pipette with flamed tip. Dissociated cells were plated at a density of approximately 4x105 
cells/ml on glass cover slips pre-coated with poly-D-lysine and mouse laminin (Becton 
Dickinson Biosciences, Oxford, UK), and maintained in an incubator (37oC and 
humidified atmosphere of 95% O2 and 5% CO2) in serum-deprived medium containing B-
27 supplement (Invitrogen, Paisley, UK) to maintain neuronal survival. Between 5 and 9 
days in culture, 5 μM cytosine β-D-arabinofuranoside (AraC, Sigma-Aldrich, Poole, UK) 
was supplemented to the medium to reduce the proliferation of non-neuronal cells. A 
heterogeneous population of hippocampal neurones was thus maintained for 4 weeks in 
culture. Neurones selected for patch-clamp recordings had somatic diameters of 15-30 
μm, with neurite extensions.  
 
Whole-cell voltage-clamp recordings were carried out 18-25 days after plating. 
During recordings, cells were continuously superfused (2 ml/min) with extracellular 
solution containing (in mM): NaCl 145, KCl 2, KH2PO4 1.18, HEPES 10, MgSO4 1.2, 
CaCl2 2, D-glucose 11, kynurenic acid 5 (glutamate receptor antagonist), atropine 0.1 μM 
(muscarinic ACh receptor antagonist) at room temperature (pH adjusted to 7.2 with 
NaOH). Recordings were carried out using an Axopatch 200B amplifier (Axon 
Instruments, Foster City, CA, output cut-off frequency = 5 kHz) at holding potential (Vh) 
of +20 mV for GABAergic postsynaptic currents (PSCs). Signals were digitised every 50 
μs and analysed off-line with PClamp8 software (Axon Instruments, Foster City, CA). 
Patch pipettes were pulled from borosilicate glass capillaries (1.5 mm outer diameter, 
Harvard apparatus, UK), and had resistances between 5 and 7 MΩ when filled with the 
intracellular solution containing (in mM): Cs2SO4 81, NaCl 4, MgSO4 2, CaCl2 0.02, 
BAPTA 0.1, D-glucose 15, HEPES 10, ATP 3, GTP 0.1, Na-phosphocreatine 5 (pH 
adjusted to 7.2 with CsOH). For the recording of somatic K+ current, K-gluconate (130 
mM) was used instead of Cs2SO4 in pipettes, and 300 µM CdCl2 and 300 nM tetrodotoxin 
(TTX) were added to the extracellular solution to block voltage-gated Ca2+ and Na+ 
channels, respectively. Series resistance of the recordings was monitored before and after 
each drug application, and recordings were excluded from analysis when series resistance 
changed by more than 10%. Changes in amplitude, frequency and duration of PSCs were 
summed by measuring the total charge transfer for a 20 s period from the onset of agonist 
perfusion. 
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Drugs were diluted at their final concentration in the extracellular solution and 
nicotinic agonists were applied via a multibarrel pipette positioned 150 μm away from the 
recorded neuron.  
 
2.2 Electrophysiological recordings of neuronal firing in the ventral tegmental area 
 
Coronal midbrain slices (350 µm) containing the ventral tegmental area (VTA) 
from male Sprague-Dawley rats (25 - 30 days old) were prepared in ice-cold, oxygenated, 
artificial cerebrospinal fluid (aCSF), which contained (in mM) NaCl 123, NaH2CO3 22, 
NaH2PO4 1.25, KCl 3.75, D-Glucose 10, CaCl2 2.5 and MgSO4 1.2. During recording, 
slices were constantly superfused with oxygenated aCSF at a flow rate of 3 ml/min at 
34oC. The VTA was visually identified as a grey area medial to the substantia nigra and 
the medial lemniscus, a white fibre tract. Single cell extracellular recordings were made 
using glass microelectrodes filled with aCSF (impedance of 3 - 6 MΩ). Action potentials 
were recorded using an Axopatch 1D amplifier (Axon Instruments, Foster City, CA), 
digitised using CED1401 plus (CED, Cambridge, UK) and captured and stored on a PC 
using Spike 2 software (CED, Cambridge, UK). Recordings from single neurones 
displayed constant action potential amplitude and waveform. For details, see (Chen et al., 
2003).  
 
Spontaneously firing neurones in the VTA were distinguished by both 
electrophysiological and pharmacological characteristics (Grace and Onn, 1989, Johnson 
and North, 1992). The most frequently recorded neurones are the classically defined 
dopaminergic neurones, which fire spontaneous action potentials at a frequency ranging 
from 0.5 to 4 Hz and whose extracellular action potential waveform has large negative 
phase and 2.5–3 ms duration. The firing rate can be significantly suppressed by 50 µM 
dopamine. The other main type of VTA neurones exhibits shorter duration (~ 2 ms) action 
potentials at higher firing frequencies (4 – 15 Hz). Dopamine does not inhibit the firing 
rate of these classically defined non-dopaminergic, GABAergic interneurones. The 
identification of dopaminergic neurones by the electrophysiological and pharmacological 
characteristics has been challenged recently as projecting dopaminergic neurones in the 
VTA were found to exhibit more diverse electrophysiological and pharmacological 
characteristics (Margolis et al., 2006, Lammel et al., 2008). For the study of nicotinic 
modulation of VTA neuron firing, we focused on the classically defined low-frequency 
firing, putative dopaminergic neurones, which have been shown to have higher sensitivity 
to nicotine than the high-frequency firing, putative non-dopaminergic neurones (Yin and 
French, 2000). 
 
Drugs were dissolved in aCSF and delivered to the slice via a switch from control 
aCSF. An initial recording period of > 4 min was usually allowed to establish the baseline 
firing frequency of a neuron. Peak changes of frequency caused by drug application were 
calculated using at least three consecutive 10 s bins containing 15 - 120 spikes. A washing 
period (> 20 min) was given between subsequent drug applications. The effect of 
2087101 was examined by comparing the effects of nicotine before and after the 
application of 2087101 in the same neuron. 
 
2.3 [3H]Noradrenaline release from rat hippocampal slices 
 
Hippocampi slices (150 μm) from 3 rats (male Lister-Hooded rats (250 – 350 g) 
were chopped using a McIlwain tissue chopper, each time rotating the tissue through 60°. 
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Slices were dispersed in Krebs bicarbonate buffer (in mM): NaCl 118, KCl, 2.4, 
CaCl2.2H2O 2.4, KH2PO4 1.2; MgSO4.7H2O 1.2, NaHCO3 25,  glucose 10, ascorbic acid 1 
(oxygenated with 5% CO2/95% O2 for 1h), and then incubated with 10 μM pargyline, a 
monoamine oxidase inhibitor, and incubated with [3H]noradrenaline (100 nM) for 30 min 
at 37°C (Dajas-Bailador et al., 2003, Barik and Wonnacott, 2006). Following loading, 
slices were washed with Krebs buffer containing 1 μM nomifensine (a monoamine uptake 
inhibitor) and 10 μM pargyline (Barik and Wonnacott, 2006). After washing, slices were 
loaded in each well of a 96-well GF/C filter plate (Millipore), and 70 μl of buffer ± 
antagonist/potentiator was added to each well for 5 minutes at 37°C. After this, buffer 
containing released radioactivity was removed by filtration into a 96-well collection plate. 
Slices were then stimulated for 5 min with buffer containing agonist (± 
antagonist/potentiator; 70 μl/well), and the stimulating buffer was removed into another 
96-well collection plate. 
 
Optiphase Supermix (Wallac) scintillation fluid (170 μl) was added to each well of 
the collection plates prior to being heat sealed and radioactivity quantified using a Wallac 
1450 Microbeta 96-well plate counter (Wallac Oy, Turku, Finland, counting efficiency 
25%). Radioactivity remaining in the slices was measured by digestion of the tissue in 0.2 
ml Solvable (Packard Biosciences) for 1 h followed by an addition of 0.5 ml isopropyl 
alcohol and 4.5 ml Hionic Fluor scintillation fluid (Packard Biosciences). Radioactivity 
was then quantified using a Wallac 1410 scintillation counter (Wallac Oy, Turku, Finland, 
counting efficiency 35%). 
 
Release of [3H]noradrenaline was expressed as a fraction of the total radioactivity 
contained within the slices at the time of stimulation. To compare the concentration-
dependent effect of nicotine and the effect of 2087101, the release of [3H]noradrenaline 
induced by different nicotine concentration before and during the addition of 2087101 
was normalised to that evoked by 100 μM nicotine. 
 
2.4 Reagents 
 
ACh chloride, (-)-nicotine hydrogen tartrate (nicotine), mecamylamine, atropine 
sulfate, choline chloride, kynurenic acid, bicuculline methochloride, nomifensine, 
pargyline and dopamine hydrochloride were from Sigma (Poole, Dorset, UK). Dihydro-β-
erythroidine hydrobromide (DHβE) was from Sigma-RBI, and methyllycaconitine citrate 
(MLA), D-(-)-2-Amino-5-phosphonopentanoic acid (D-AP5), 6-Cyano-7-
nitroquinoxaline-2,3-dione (CNQX) and (2S)-(+)-5,5-Dimethyl-2-morpholineacetic acid 
(SCH 50911) from Tocris Cookson Ltd (Bristol, UK). [7,8-3H]noradrenaline (8-15 
Ci/mmol) was purchased from Amersham Biosciences (Amersham, Bucks, UK). 2087101 
was synthesised by Lilly Research Laboratories (courtesy of S. Holllinshead). Stock 
solution of 10 mM were made up in DMSO, stored at –20 oC and diluted in the 
extracellular recording solution at the final concentration before use.  
 
2.5 Statistics 
 
Numerical data in the text and figures are expressed as mean ± standard error of 
the mean (S.E.M). Statistical comparisons were made with ANOVA or Student’s t-test, 
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paired or unpaired when appropriate. Values of P < 0.05 were taken to be statistically 
significant.  
 
3. Results  
3.1 Effects of 2087101 on nicotinic agonist induced postsynaptic currents in cultured 
hippocampal neurones. 
 
Activation of α7 and non-α7 nicotinic receptors in hippocampal neurones has been 
shown to stimulate somatodendritic currents (Alkondon and Albuquerque, 1993) and to 
induce action potential-dependent GABA release, which was recorded as GABAA 
receptor-mediated postsynaptic currents (PSCs) (Alkondon et al., 1999, Albuquerque et 
al., 2009). In our cultured hippocampal neurones, ACh induced somatodendritic current in 
the presence of TTX, and the effect was completely inhibited by 10 nM MLA, showing a 
predominant α7 receptor-mediated effect (Fig. 1A), which is in agreement with the low 
prevalence of non-α7 heteromeric receptor-mediated somatodendritic currents shown 
previously (Alkondon and Albuquerque, 1993, Hurst et al., 2005, Ng et al., 2007).  
 
In order to obtain both α7 and α4β2* receptor-mediated responses by the same 
mechanism, we recorded ACh-induced PSCs (Fig. 1B) in the absence of TTX and at the 
holding potential (Vh) of +20 mV to minimise the amplitude of α7-mediated 
somatodendritic currents that show inward rectification (Alkondon et al., 1999). 1 mM 
kynurenic acid and 10 µM atropine were present continuously to pharmacologically block 
ionotropic glutamate receptors and muscarinic ACh receptors. Under these conditions, the 
PSCs were sensitive to the GABAA receptor antagonist bicuculline, hence resulted from 
presynaptic GABA release (Alkondon et al., 1999). The α7-selective agonist choline (10 
mM) was able to induce PSCs in most cultured neurones (Fig. 1C top trace & D left trace) 
and the effects was inhibited by 10 nM MLA (Fig. 1C bottom trace), confirming the 
presence of an α7 component. In the presence of 10 nM MLA to block the α7 receptors, 
ACh also evoked PSCs (Fig. 1F), showing a non-α7 mediated component due to the 
activation α4β2* receptors (Alkondon et al., 1999, Albuquerque et al., 2009). The overall 
ACh-induced response was significantly inhibited by MLA at a higher concentration (100 
nM)  (Fig. 1B, bottom trace) that inhibits both α7 and non-α7 receptors (Alkondon and 
Albuquerque, 1993). We have therefore examined the effects of 2087101 on PSCs 
induced by choline and ACh + MLA (10 nM) to activate the α7 and the non- α7, α4β2* 
components separately. 
 
The application of 2087101 (3 μM) caused no currents in hippocampal neurones on 
its own, but in the presence of 3 μM 2087101, the frequency and duration of PSCs 
induced by both choline and ACh + MLA were enhanced in a reversible manner (Fig. 1D 
and F, middle and right traces). To quantify the changes in PSCs, total charge transfer for 
a 20 s period was measured starting from the application of agonist (Alkondon et al., 
1999). By comparing to agonist-induced responses before the addition of 2087101 in each 
neuron, we found significantly enhanced agonist-evoked effects in the presence of 
2087101 (10 min) and the effect was washed out (Fig. 1E and G, * P < 0.05, One-way 
ANOVA with Dunnett’s posthoc test for multiple comparisons against the control). 
Averaged enhancements for choline and ACh + MLA induced responses were 247 ± 14% 
(n = 5) and 235 ± 27% of control (n = 6), respectively. The results show that 2087101 
significantly potentiated agonist-induced α7 and α4β2* receptor-mediated GABA release.  
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In order to ascertain that 2087101 indeed potentiated nicotinic acetylcholine receptors 
but not GABAA receptors to facilitate the PSCs, we examined its effect on postsynaptic 
GABAA receptors in hippocampal neurones. It is particularly important to examine this 
possible cross reactivity because the binding site for 2087101 on α7 receptors has been 
shown to be a conserved allosteric site within the whole family of Cys-loop ligand-gated 
ion channel receptors, which include both nicotinic and GABAA receptors (Hosie et al., 
2006, Young et al., 2008) 
 
Using whole-cell patch clamp recordings at the Vh of +20 mV and in the presence 
of 10 µM SCH-50911, a GABAB receptor-selective antagonist, direct application of 
GABA (5 µM) induced an outward whole-cell current mediated by GABAA receptors. 
Application of 2087101 (3 μM for 7 min) did not cause any whole-cell current by itself, 
nor any significant alteration of GABA-induced currents (P > 0.05, n = 5), showing a lack 
of direct activity of 2087101 on GABAA receptors.  
 
We have shown previously that 2087101 has no effect on voltage-gated Ca2+ or 
Na+ channels or ionotropic glutamate receptors in cultured cortical neurones (Broad et al., 
2006). We have now examined its effects on voltage-gated K+ channels, since their 
modulation may indirectly affect GABA release. Outward currents were activated by a 
depolarising voltage step from -70 to +20 mV using a K+-gluconate containing patch 
pipette in the extracellular solution containing 300 µM CdCl2 and 300 nM TTX to block 
the voltage-gated Ca2+ and Na+ channels, respectively. The application of 2087101 (3 μM 
for 7 min) did not affect these voltage-gated K+ current (n = 5). Altogether, these 
experiments show a lack of effects of 2087101 on either GABAA receptors or voltage-
gated K+ channels, and thus further support the evidence of selective modulation of α4β2* 
and α7 nicotinic acetylcholine receptors. 
 
3.2 Effects of 2087101 on nicotine-stimulated [3H]noradrenaline release in the 
hippocampus. 
 
In contrast to the nicotinic acetylcholine receptor mediated GABA release, 
nicotine-stimulated noradrenaline release in the hippocampus is not sensitive to the α7 
antagonist MLA or the β2-preferring antagonist dihydro-β-erythroidine (DHβE), but is 
partially inhibited by the α3-preferring antagonist α-conotoxin AuIB (Clarke and Reuben, 
1996, Luo et al., 1998), so that α3β4* receptors could be the main subtype mediating this 
process (Vizi and Kiss, 1998). Because 2087101 has been shown to have no allosteric 
effect on recombinant α3β4 receptors (Broad et al., 2006), we examined its effect on 
nicotine-stimulated [3H]noradrenaline release in rat hippocampal slices. 
 
Nicotine caused a concentration-dependent increase of fractional 
[3H]noradrenaline release (Fig. 2 filled circles) with an EC50 of 5.8 μM, which is very 
similar to that reported for nicotine-induced [3H]noradrenaline release from synaptosomes 
(6.5 μM) (Clarke and Reuben, 1996). The non-competitive nicotinic antagonist 
mecamylamine (MEC, 10 µM, n = 6,), but not DHβE (2 µM, n = 6), blocked nicotine-
induced [3H]noradrenaline release, in agreement with the notion that α3β4*, but not 
α4β2*, receptors are the predominant subtype in this process (Vizi and Kiss, 1998).  
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Application of 3 µM 2087101 alone did not induce any [3H]noradrenaline release 
in hippocampal slices. In the presence of the potentiator, nicotine-induced concentration-
dependent release (Fig. 2 open circles) was found similar to that of nicotine alone (EC50: 
4.2 μM versus 5.8 μM, and EMax: 94.0 ± 7.9 % versus 99.5 ± 4.1 %, n = 6 each). 
Mecamylamine (10 µM) also blocked the effects of nicotine + 2087101 (Fig. 2 open 
diamond). Two-way ANOVA analysis of the two curves showed significant (F[10, 110] = 
51.2, P < 0.001) concentration-dependent effects of nicotine, but no significant effect of 
2087101 (F[1, 110] = 0.12, P > 0.05).  
 
The nicotine concentration-response curves were fitted by a one-site sigmoidal 
equation, showing no evidence for a low affinity α7 component that was shown 
previously to be activated by choline or anatoxin in hippocampal slices (Barik and 
Wonnacott, 2006). The lack of significant effect of 2087101 on nicotine-induced 
[3H]noradrenaline release thereby agrees with its lack of effect on α3β4 receptors.  
 
 
3.3 Effects of 2087101 on nicotine-stimulated neuronal firing in the VTA. 
 
The spontaneous firing activity of midbrain dopamine neurones in rat brain slices 
can be enhanced by submicromolar concentrations of nicotine via the activation of β2* 
nicotinic receptors (Picciotto et al., 1998), which may include the α4β2, α6β2, α4α5β2 
and α4α6β2β3 subtypes in the VTA (Klink et al., 2001, Champtiaux et al., 2003). Albeit 
at a lower density, α7 receptors are also expressed in the VTA at pre- and postsynaptic 
locations to modulate glutamate release and somatodendritic currents (Mansvelder and 
McGehee, 2000, Klink et al., 2001). Given the essential role of nicotinic receptors in the 
VTA for nicotine re-enforcement, we examined whether 2087101 can enhance nicotine-
stimulated neuronal firing activity in rat brain slices. 
 
Bath-applied nicotine at 0.3 µM significantly increased the firing rate of the 
putative dopamine neurones by 46.4 ± 4.4% from baseline (mean baseline  firing 
frequency = 1.9 ± 0.1 Hz, range 0.7 – 3.5 Hz, n = 61, Fig. 3A). The effect of nicotine was 
concentration-dependent with 0.3 µM nicotine producing a sub-maximal effect (Fig. 3B). 
In contrast, the firing frequency of the putative non-dopamine neurones was much less 
sensitive to bath-applied nicotine, where 1 µM nicotine caused no significant firing rate 
increase (1.4 ± 1.4%, baseline frequency = 6.7 ± 0.7 Hz, range 5.4 – 8.4 Hz, n = 4), in 
agreement with a previous finding (Yin and French, 2000). Subsequently, we examined 
the effect of 2087101 on nicotine-stimulated firing rate increase in the putative dopamine 
neurones. 
 
Repeated applications of 0.3 µM nicotine with a 20 min washing period in-
between produced identical increases in firing rate in dopamine neurones (44.3 ± 7.6 % 
vs. 45.4 ± 7.3 %, n = 9, P = 0.5, paired t-test, Fig. 3A). Pre-application (10 min) of 10 µM 
2087101 before the second application of nicotine significantly enhanced the response by 
29 ± 11% compared to the control nicotine response (n = 10, * P < 0.05, paired t-test, Fig. 
3C). However, the effect of 3 µM 2087101 was not statistically significant (P > 0.05, n = 
16, paired t-test). Fig. 3D shows the % enhancement of 0.3 µM nicotine-stimulated 
response by 0, 3 and 10 µM 2087101. The nicotinic potentiator can thus concentration-
dependently facilitate the effect of nicotine on dopamine neurones in the VTA. 
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2087101 (at 3 and 10 µM) had no significant effects on baseline firing rate (2.2 ± 
1.6 % change, n = 27, see Fig. 3C), or action potential waveform (data not shown), 
showing no direct activation of nicotinic receptors or other receptors/channels. The 
potential nicotinic receptor subtypes activated by 0.3 µM nicotine was examined using 
nicotinic antagonists. DHβE (2 µM) significantly inhibited the response (91 ± 5% 
inhibition, n = 3, Fig. 3E), but α-conotoxin MII (CTX, 100 nM, an α6 antagonist) or MLA 
(10 nM, an α7 antagonist) had no significant effects (14 ± 8 % inhibition, n = 4 and 4.8 ± 
2.1% inhibition, n = 3, respectively, Fig. 3E), suggesting a major role for the α4β2* 
receptors under the experimental conditions. The effect of 2087101 could therefore be 
caused by potentiation of α4β2* receptors in the VTA. 
 
Because the excitatory effect of nicotine could arise not only directly from the 
activation of somatodendritic nicotinic receptors, but also indirectly from the release of 
excitatory neurotransmitters glutamate or ACh, we examined the effects of glutamate 
receptor antagonists (50 µM D-AP5, an NMDA receptor antagonist, and 20 µM CNQX, 
an AMPA receptor antagonist, n = 3) and the muscarinic ACh receptor antagonist 
atropine (1 µM, n = 4). The antagonists had no significant effect on 0.3 µM nicotine-
induced response or the basal spontaneous firing rate. The result is in support of a direct 
somatodendritic effect by nicotine, in agreement with the effect by a α4β2-selective 
agonist TC-2559 shown by us previously (Chen et al., 2003).  
 
(Figure 3 near here) 
 
4. Discussion  
 
We showed that the nicotinic allosteric modulator 2087101 significantly facilitated 
nicotinic stimulation of GABA release in the hippocampus and dopamine neuron firing in 
the VTA, but it had no effect on nicotine-induced noradrenaline release in the 
hippocampus. The differential facilitation of these nicotinic processes agrees with its 
selectivity for different receptor subtypes (Broad et al., 2006). Based on the present 
knowledge of native nicotinic receptor subunit compositions, our results suggest that 
2087101 is active on neuronal processes mediated by α4β2* and α7, but not α3β4* 
nicotinic receptors. The selectivity profile of 2087101 on recombinant receptors therefore 
translates very well to native nicotinic receptor subtypes.  
 
The activity of 2087101 on native α7 receptors has been clearly demonstrated in 
hippocampal neurones. The α7 receptor selective agonist choline (Alkondon et al., 1999) 
was used to induce GABAergic PSCs, and the process was enhanced by ~1.5 fold by 
2087101, without any effect on GABAA receptors, demonstrating unequivocally the 
potentiator’s activity on native α7 receptors. Restricted by the lack of subtype selective 
agonists and antagonists for heteromeric nicotinic receptors (Albuquerque et al., 2009), 
we examined the effects of 2087101 on non-α7 nicotinic receptor-mediated hippocampal 
GABA release using ACh in the presence of MLA, an α7-selective antagonist. This 
process was also enhanced by 2087101. As the non-α7 component of hippocampal 
GABA release was shown to be mainly mediated by α4β2* nicotinic receptors (Alkondon 
et al., 1999) and amongst those 80% were identified to be of the α4β2 composition 
(McClure-Begley et al., 2009), 2087101 may have therefore potentiated the hippocampal 
α4β2 receptors.  
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Although the subunit composition has yet to be confirmed at the molecular level, 
nicotine-induced hippocampal [3H]noradrenaline release has been proposed to be 
mediated by (non-α7, non-α4β2) α3β4* nicotinic receptors (Vizi and Kiss, 1998), with 
the pharmacological characteristics very similar to those recently identified α3β4* 
receptors expressed in the habenulo-interpeduncular pathway mediating ACh release 
(Grady et al., 2009). 2087101 was, however, not able to potentiate nicotine-induced 
[3H]noradrenaline release, a finding in agreement with its lack of activity on recombinant 
α3β4 receptors in heterologous expression systems (Broad et al., 2006). These differential 
effects of 2087101 on hippocampal GABA and noradrenaline release have therefore 
suggested its selectivity for native α4β2* and α7, but not α3β4* receptors. 
 
We have also further demonstrated the activity of 2087101 on nicotinic receptors 
in the VTA. The stimulatory effect of 0.3 µM nicotine on putative dopamine neurones 
was significantly enhanced by 2087101. The nicotinic receptor subtypes underlying the 
effect were investigated using antagonists. DHβE, but not MLA or α-conotoxin MII, 
produced significant inhibition, suggesting the activation of α4β2* receptor subtypes, the 
predominant subtype in the VTA (Zoli et al., 1998, Klink et al., 2001, Champtiaux et al., 
2003). The lack of a significant contribution by α7 receptors could be explained by the 
relatively low density of α7 receptors in the brain area (Zoli et al., 1998). Although 
nicotine can stimulate glutamate release via presynaptic α7 receptors and increased the 
frequency of excitatory postsynaptic currents in postsynaptic neurones (Mansvelder et al., 
2000), we found that the block of glutamatergic transmission had no influence on 
nicotine-stimulated firing rate increase. The increased glutamate release may therefore 
have negligible effect on the firing rate of putative dopamine neurones when compared 
with the direct somatodendritic depolarisation induced by nicotine. It is also noted that a 
slightly higher concentration of 2087101 is required to significantly facilitate nicotine-
induced dopamine neuron firing rate increase. It may be speculated that the incorporation 
of additional subunits, i.e. α5 and β3, by the α4β2* nicotinic receptors in the VTA (Zoli 
et al., 1998, Klink et al., 2001, Champtiaux et al., 2003) may reduce the potency of 
2087101. 
 
Receptor subunit composition could indeed influence the potency and/or efficacy 
of allosteric modulators. Several intrasubunit (Curtis et al., 2002) and intersubunit sites 
(Hansen and Taylor, 2007) have been identified on α4β2 receptors that were shown to 
specifically interact with certain allosteric modulators. The allosteric binding site of 
2087101 on α7 receptors was identified as an intrasubunit hydrophobic cavity (Young et 
al., 2008). As this binding site is a conserved allosteric site present in various members of 
the family of cys-loop ligand-gated ion channels receptors (Young et al., 2008), it is 
possible to envisage a corresponding allosteric site on the α4 subunit. However, the lack 
of activity on α3β4 receptors in heterologous expression systems (Broad et al., 2006) and 
in the rat hippocampus may suggest that the modulator does not bind the α3 subunit.  
 
The ability of 2087101 to enhance GABAergic activity could be beneficial for 
many severe neurological disorders, including Alzheimer’s disease and schizophrenia 
(Freedman et al., 2000, Perry et al., 2000). Indeed, the α7-selective potentiators were also 
shown to facilitate GABA release in the hippocampus to normalise sensory gating deficits 
in animal models (Hurst et al., 2005) and to improve cognitive functions in behavioural 
paradigms (Ng et al., 2007, Timmermann et al., 2007). An α7 and α4β2 dual potentiator 
may thus not only enhance α7-mediated GABA release but also α4β2-mediated effects. 
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The latter may be particularly beneficial to schizophrenia patients, because the α7 
receptor expression and functions are significantly reduced in this disorder (Freedman et 
al., 2000). GABA release in many brain regions has been shown to be predominantly 
modulated by both α7 and α4β2* receptors (Albuquerque et al., 2009), so that 2087101 
and similar compounds could exert significant concurrent activity across many brain areas 
to offer better therapeutic potencies for some indications than subtype-selective allosteric 
potentiators. 
 
The dual facilitation of both the GABAergic and dopaminergic systems may also 
ameliorate cognitive and psychiatric deficits. Dopaminergic transmission in the brain is 
known to modulate cognitive and reward processes as well as neuropsychiatric symptoms 
(Wise, 2004). A synergy between GABAergic and dopaminergic systems may thus be 
explored for cognitive enhancement. 
 
This in vitro demonstration of the potentiator activity may encourage future in vivo 
behavioural evaluations for its therapeutic potentials. Because of its lack of activity on 
acetylcholinesterase (Broad et al., 2006) or α3β4* receptors, 2087101 may show a much 
improved side effect profile compared to galantamine, an acetylcholinesterase inhibitor 
and a non-selective nicotinic receptor allosteric modulator, which is used clinically for the 
symptomatic treatment of Alzheimer’s disease.  
 
In summary, the nicotinic positive allosteric modulator, 2087101, significantly 
potentiated native nicotinic processes mediated by α4β2* and α7, but not α3β4* nicotinic 
receptors. The selectivity profile of 2087101 may be further explored to differentiate the 
allosteric binding sites between heteromeric receptors. In addition, this potentiator can be 
used to further evaluate the therapeutic potential of concurrent enhancement of both α7 
and α4β2*-mediated nicotinic processes in the brain for the improvements of cognitive, 
motor and reward functions.  
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Figure legends 
 
Fig. 1 2087101 enhanced nicotinic receptor agonist-induced GABA release in cultured rat 
hippocampal neurones. A. Acetylcholine (ACh, 1mM) in the presence 1 µM TTX induced 
somatodendritic current (top trace) and the effect was inhibited by 10 nM MLA, a α7 
selective antagonist (bottom trace). B. ACh in the absence of TTX induced postsynaptic 
currents (PSCs), which were recorded as outward current at a holding potential of +20 
mV to minimise the amplitude of somatodendritic current as it inward rectifies (top trace). 
ACh-induced PSCs were inhibited by MLA at the high concentration of 100 nM, which 
antagonised both α7 and non-α7 nicotinic components (bottom trace). C. The α7-
selective agonist choline (10 mM) induced PSCs (top trace) that were sensitive to 10 nM 
MLA (bottom trace). Choline (D) and ACh in the presence of 10 nM MLA (ACh + MLA) 
(F) induced PSCs in the control aCSF (left traces), during the 10 min application of 
2087101 (3 µM, middle traces) and after washing out (right traces). Filled horizontal bars 
indicating agonist application periods and the open horizontal bars show the presence of 3 
μM 2087101. During the experiments, agonists were applied every two minutes. Changes 
in PSC frequency and duration were measured by total charge transfer for a 20 s period 
from the start of each agonist application and the values were normalised to agonist’s 
effect prior to the addition of 2087101 in each experiment. Averaged time courses for the 
effects of 2087101 on PSCs induced by 10 mM choline (E, n = 5) or 1 mM ACh + 10 nM 
MLA (G, n = 6) are shown. During the application of 2087101 (marked as a grey 
shadowed area), significant increases of agonist-induced PSCs were found (*P < 0.05, 
One-way ANOVA with Dunnett’s posthoc test), and recovery was seen during the 
washing out of 2087101. 1 mM kynurenic acid and 10 µM atropine were present in the 
aCSF throughout the experiments. PSCs were recorded at the holding potential of +20 
mV. Values are shown as mean ± S.E.M. 
 
Fig. 2. Nicotine-induced concentration-dependent [3H]noradrenaline release in  rat 
hippocampal slices in the presence (open circles, Nic + 2087101) and absence (filled 
circles, Nic) of 3 M 2087101. Fractional release of preloaded [3H]noradrenaline (mean 
± S.E.M from 6 independent experiments) was measured following 5 min application of 
nicotine with or without 2087101 in 96-well plates. The concentration-response curves 
were fitted to a one-site sigmoidal equation and the EC50 for nicotine + 2087101 and 
nicotine alone were obtained at 4.2 μM (LogEC50 = -6.63 ± 0.16 M) and 5.8 μM 
(LogEC50 = -6.77 ± 0.07 M), respectively. Maximal fractional release relative to that 
induced by 100 μM nicotine were found at 99.5 ± 4.1 % for nicotine and 94.0 ± 7.9 % for 
nicotine + 2087101. No statistical difference was found for the effect of 2087101 (P > 
0.05), although there was a significant effect for nicotine concentration (P < 0.05, Two-
way ANOVA). Mecamylamine (MEC) at 10 µM completely inhibited 100 µM nicotine-
induced release in the presence and absence of 2087101 (diamond). Data points are mean 
± S.E.M. 
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Fig. 3 2087101 enhanced nicotine-induced firing rate increase of putative dopamine 
neurones in the VTA in rat brain slices. A. Bath applications of 0.3 µM nicotine (filled 
horizontal bars) increased the spontaneous firing rate of dopamine neurones. Firing 
frequencies were calculated from the number of spikes in three 10s bins before and after 
nicotine application in the rate histogram.  B. A plot of nicotine-induced % increases of 
firing rates at the indicated concentrations shows that 0.3 µM nicotine elicited sub-
maximal effects on firing frequency. C. The presence of 10 µM 2087101 (open bar) 
enhanced nicotine (filled bars)-induced firing frequency increase without causing any 
effect on its own. D. % changes from paired control applications of nicotine in the 
presence 0, 3 and 10 µM 2087101 are shown. * P < 0.05 indicates significantly enhanced 
nicotine-induced firing rate increase in the presence of 10 µM 2087101. E. % inhibition 
caused by nicotinic receptor antagonists dihydro-beta-erythroidine (DHβE), α-conotoxin 
MII (CTX) and methyllycaconitine (MLA) on 0.3 µM nicotine induced response. All 
values are presented as mean ± S.E.M. 
 
Acknowledgement. The authorsacknowledge Tristan Baldwinson, Thomas Sharples, 
Colin Davies, Federica Sasdelli, and Elisiana Tafi for experimental assistance, Drs. Lisa 
Broad and Ian A. Pullar for discussions. 
  
Statement of conflicts of interest. 
The manuscript is approved for publication by Eli Lilly & Co. and there are no other 
conflicts of interest known to all authors. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 17
Fig. 1 
 
 
 
 
 
 
 
 
 
 
 18
Fig. 2 
 
 
  
 
 
 
 19
Fig. 3 
 
 
